久久久久免费_精品国产乱码久久久久久久软件_欧美一区亚洲一区_国产一区二区三区高清在线观看_欧美日在线观看_成人网av

美國Golden Helix?
Golden Helix, Inc.成立于1998年,(數(shù)據(jù)挖掘和化合物篩選軟件)
Founded in 1998, Golden Helix has become the global leader in SNP and copy number analysis, genetic association software, and analysis services. Using advanced technologies, Golden Helix provides a comprehensive suite of software tools that empower genetic analysis at unprecedented levels of scope, depth, and ease, enabling its customers to determine the genetic causes of disease, transform drug discovery, create genetic diagnostics, and advance the quest for personalized medicine. Used by hundreds of researchers at the world's top pharmaceutical, biotech, and academic research organizations, their products have been cited in over 100 peer-reviewed publications that detail groundbreaking research uncovering the genetic and environmental basis of disease.

Golden Helix is an innovative leader in data analysis software and predictive analytics. Our tools and services are used by top researchers and analysts around the world for tasks that require truly advanced analytics, such as finding the genetic causes of disease, predictive compound screening for drug discovery, and developing (industry-leading) risk, attrition, and segmentation models for leading commercial entities.

Where We Are Located
Golden Helix is located in Bozeman, MT about 90 miles north of Yellowstone National Park and nestled in the heart of the Rocky Mountains. Bozeman is the home of Montana State University and boasts several articles recently in the popular press (US News, Fast Company, MSN City Guides, and Forbes Magazine) highlighting its breath-taking scenery and ideal locale for hi-tech start-up companies. Bozeman was also ranked #1 by Bizjournal as offering the best quality of life among any city in the U.S.!

Founded in September 1998 in Bozeman, Montana, Golden Helix is an industry leader in predictive analytics, with its extraordinary recursive partitioning engine currently in use at eight of the world’s top ten pharmaceutical companies, dozens of globally renowned academic institutions, several federal governments, and many leading commercial companies.

In 1998, Dr. Christophe Lambert teamed up with Dr. Doug Hawkins from the University of Minnesota to develop a tree-based recursive partitioning tool capable of performing multivariate analysis. Dr. Hawkins and Dr. Lambert developed a unique, patented algorithm for real time analysis of data sets of virtually unlimited size called Formal Inference-based Recursive Modeling, or FIRM. FIRM technology proved to be incredibly powerful and is still the only tree-based approach to discover true multi-way splits in addition to offering a simple and intuitive user interface, forests of random trees, and multivariate analysis.

In the late 1990’s, a new branch of genomics, single nucleotide polymorphism (SNP) analysis, was becoming increasingly popular among genetic researchers. Researchers were attempting to uncover associations between genetic and environmental factors and disease using large numbers of patients and massive amounts of genetic data.

Golden Helix realized that its fast recursive partitioning algorithm would be ideal for researchers attempting to uncover significant associations within the human genome. In late 1998, GlaxoSmithKline, then Glaxo-Wellcome, invested in Golden Helix to develop HelixTree, the world’s leading SNP analysis software.

At the same time, Golden Helix also recognized the need for a fast and efficient tool in the field of cheminformatics that would enable researchers to quickly and accurately identify target compounds for drug development. Concurrent with the release of HelixTree, Golden Helix unveiled ChemTree, an authoritative tool for determining the quantitative structure activity relationships (QSAR’s) of compounds to aid researchers seeking chemical compounds for the creation of new drugs.

From 2001 to 2005, Golden Helix received federal grants from the National Institutes of Health to fund extensive R&D for HelixTree. With this funding and the increasing demand for cutting edge SNP analysis software, Golden Helix focused its development and marketing efforts towards HelixTree, expanding and enhancing the elegant, intuitive workflow and interface of the FIRM technology to develop an unparalleled SNP analysis tool.

Today, Golden Helix continues to develop its products and services, which now encompass three major platforms: SNP & Variation, Drug Discovery and Predictive Analytics. Golden Helix’s products remain the industry standard and have been cited in over 100 peer reviewed articles. Golden Helix is committed to Accelerating the Quest for Significance!
?